Turnitin
降AI改写
早检测系统
早降重系统
Turnitin-UK版
万方检测-期刊版
维普编辑部版
Grammarly检测
Paperpass检测
checkpass检测
PaperYY检测
CAR-T cell therapy in hematological malignancies: current opportunities and challenges
X Zhang, L Zhu, H Zhang, S Chen, Y **ao - Frontiers in immunology, 2022 - frontiersin.org
Chimeric antigen receptor T (CAR-T) cell therapy represents a major breakthrough in cancer
treatment, and it has achieved unprecedented success in hematological malignancies …
treatment, and it has achieved unprecedented success in hematological malignancies …
Mechanisms of resistance to chimeric antigen receptor-T cells in haematological malignancies
Chimeric antigen receptor (CAR)-T cells have recently emerged as a powerful therapeutic
approach for the treatment of patients with chemotherapy-refractory or relapsed blood …
approach for the treatment of patients with chemotherapy-refractory or relapsed blood …
Risk of second tumors and T-cell lymphoma after CAR T-cell therapy
Background The risk of second tumors after chimeric antigen receptor (CAR) T-cell therapy,
especially the risk of T-cell neoplasms related to viral vector integration, is an emerging …
especially the risk of T-cell neoplasms related to viral vector integration, is an emerging …
Infections after chimeric antigen receptor (CAR)‐T‐cell therapy for hematologic malignancies
Background Chimeric antigen receptor (CAR)‐T‐cell therapies have revolutionized the
management of acute lymphoblastic leukemia, non‐Hodgkin lymphoma, and multiple …
management of acute lymphoblastic leukemia, non‐Hodgkin lymphoma, and multiple …
Severe hematotoxicity after CD19 CAR-T therapy is associated with suppressive immune dysregulation and limited CAR-T expansion
K Rejeski, A Perez, G Iacoboni, V Blumenberg… - Science …, 2023 - science.org
Prolonged cytopenias after chimeric antigen receptor (CAR) T cell therapy are a significant
clinical problem and the underlying pathophysiology remains poorly understood. Here, we …
clinical problem and the underlying pathophysiology remains poorly understood. Here, we …
Infectious complications, immune reconstitution, and infection prophylaxis after CD19 chimeric antigen receptor T-cell therapy
K Wudhikarn, MA Perales - Bone marrow transplantation, 2022 - nature.com
CD19-targeted chimeric antigen receptor (CAR) T-cell becomes a breakthrough therapy
providing excellent remission rates and durable disease control for patients with …
providing excellent remission rates and durable disease control for patients with …
Single-center experience using anakinra for steroid-refractory immune effector cell-associated neurotoxicity syndrome (ICANS)
In addition to remarkable antitumor activity, chimeric antigen receptor (CAR) T-cell therapy is
associated with acute toxicities such as cytokine release syndrome (CRS) and immune …
associated with acute toxicities such as cytokine release syndrome (CRS) and immune …
Early cytopenias and infections after standard of care idecabtagene vicleucel in relapsed or refractory multiple myeloma
JM Logue, LC Peres, H Hashmi… - Blood …, 2022 - ashpublications.org
Idecabtagene vicleucel (ide-cel) was FDA-approved in March 2021 for the treatment of
relapsed/refractory multiple myeloma after 4 lines of therapy. On the KarMMa trial, grade≥ 3 …
relapsed/refractory multiple myeloma after 4 lines of therapy. On the KarMMa trial, grade≥ 3 …
Infectious complications in patients with relapsed refractory multiple myeloma after BCMA CAR T-cell therapy
S Kambhampati, Y Sheng, CY Huang… - Blood …, 2022 - ashpublications.org
B-cell maturation antigen-targeted chimeric antigen receptor T-cell therapy (BCMA CAR-T)
is an effective treatment of relapsed refractory multiple myeloma (MM). However, the pattern …
is an effective treatment of relapsed refractory multiple myeloma (MM). However, the pattern …
CAR T-cell therapy for B-cell lymphoma
N Denlinger, D Bond, S Jaglowski - Current problems in cancer, 2022 - Elsevier
Chimeric antigen receptor-modified (CAR) T-cell therapy targeting CD19 has revolutionized
the treatment of relapsed or refractory B-cell lymphomas. Based on unprecedented …
the treatment of relapsed or refractory B-cell lymphomas. Based on unprecedented …